Earlier detection can help avoid many serious complications of peripartum cardiomyopathy

Future Cardiology

Volumn 9, Issue 6, 2013, Pages 809-816

  Fett, James D ^a,b,c  

^a Deschapelles Haiti   (United States)

^b Peripartum Cardiomyopathy Network   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

heart failure; Investigations in Pregnancy Associated Cardiomyopathy; outcomes; peripartum cardiomyopathy; PPCM; pregnancy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; BROMOCRIPTINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PENTOXIFYLLINE;

AFRICAN AMERICAN; ANKLE EDEMA; AUTOPSY; AWARENESS; BLOOD PRESSURE; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; CONGESTIVE CARDIOMYOPATHY; COUGHING; DELAYED DIAGNOSIS; DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPNEA; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EMERGENCY WARD; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNE SYSTEM; INNATE IMMUNITY; INTESTINE INFARCTION; LEFT VENTRICULAR ASSIST DEVICE; LUNG EMBOLISM; NONHUMAN; OUTCOME ASSESSMENT; PARITY; PERINATAL PERIOD; PERIPARTUM CARDIOMYOPATHY; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SUDDEN CARDIAC DEATH; SWELLING; SYSTOLIC DYSFUNCTION; THROMBOEMBOLISM; WEIGHT GAIN;

CARDIOMYOPATHIES; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; EARLY DIAGNOSIS; FEMALE; HUMANS; INCIDENCE; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROGNOSIS; RECOVERY OF FUNCTION; SURVIVAL RATE; THROMBOEMBOLISM; VENTRICULAR FUNCTION, LEFT; WOMEN'S HEALTH; WORLD HEALTH;

EID: 84887239327     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.13.63     Document Type: Review

References (50)

1. Pearson GD, Veille JC, Rahimtoola S et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283(9), 1183-1188 (2000).
2. Hibbard JU, Lindheimer M, Lang RM. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet. Gynecol. 94, 311-316 (1999).
3. Elkayam U, Akhter MW, Singh H et al. Pregnancy-associated cardiomyopathy: Clinical characteristics and a comparison between early and late presentation. Circulation 111, 2050-2055 (2005).
4. Brown CS, Bertolet BD. Peripartum cardiomyopathy: A comprehensive review. Am. J. Obstet. Gynecol. 178, 409-414 (1988).
5. Safirstein JG, Ro AA, Grandhi S, Wang L, Fett JD, Staniloae C. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int. J. Cardiol. 154(1), 27-31 (2012).
6. Goland S, Modi K, Bitar F et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J. Cardiac Fail. 15, 645-650 (2009).
7. Sliwa K, Fett JD, Elkayam U. Seminar: Peripartum cardiomyopathy. Lancet 368, 687-693 (2006).
8. Cruz MO, Briller J, Hibbard JU. Update on peripartum cardiomyopathy. Obstet. Gynecol. Clin. North Am. 37, 283-303 (2010).
9. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: Diagnosis, prognosis, and management. J. Am. Coll. Cardiol. 58, 659-667 (2011).
10. Goland S, Bitar F, Modi K et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J. Card. Fail. 17, 426-430 (2011).
11. Harper MA, Meyer RE, Berg CJ. Peripartum cardiomyopathy: Population-based birth prevalence and 7-year mortality. Obstet. Gynecol. 120(5), 1013-1019 (2012).
12. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am. Heart J. 152, 509-513 (2006).
13. Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am. J. Obstet. Gynecol. 201, 171.e1-171.e5 (2009).
14. Fett JD, Sannon H, Thelisma E, Sprunger T, Suresh V. Recovery from severe heart failure following peripartum cardiomyopathy. Int. J. Gynecol. Obstet. 104(2), 125-127 (2009).
15. Fett JD, Christie LG, Carraway RD, Sundstrom JB, Ansari AA, Murphy JG. Unrecognized peripartum cardiomyopathy in Haitian women. Int. J. Gynaecol. Obstet. 90, 161-166 (2005).
16. Fussell KM, Awad JA, Ware LB. Case of fulminant hepatic failure due to unrecognized peripartum cardiomyopathy. Crit. Care Med. 33, 891-893 (2005).
17. Fett JD. Validation of a self-test for early diagnosis of heart failure in peripartum cardiomyopathy. Crit. Pathw. Cardiol. 10, 44-45 (2011).
18. Ellis JE, Ansari AA, Fett JD et al. Inhibition of progenitor dendritic cell maturation by plasma from patients with peripartum cardiomyopathy: Role in pregnancy-associated heart disease. J. Clin. Develop. Immunol. 12, 265-273 (2005).
19. Fett JD, Dowell DL, Carraway RD, Sundstrom JB, Ansari AA. 100 cases of peripartum cardiomyopathy and counting: What's going on Int. J. Cardiol. 97(3), 571-573 (2004).
20. Tanous D, Siu SC, Mason J et al. B-type natriuretic peptide in pregnant women with heart disease. J. Am. Coll. Cardiol. 56, 1247-1253 (2010).
21. American Heart Association. The AHA Guidelines and Scientific Statements Handbook. Fuster V (Ed.). Wiley-Blackwell, Oxford, UK (2009).
22. European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur. Heart J. 33, 1787-1847 (2012).
23. Ansari AA, Fett JD, Carraway RD, Mayne AE, Onlamoon M, Sundstrom JB. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin. Rev. Allergy Immunol. 23, 301-324 (2002).
24. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1 and TH17-mediated autoimmunity. Proc. Natl Acad. Sci. USA 106(35), 14948-14953 (2009).
25. Godsel LM, Leon JS, Wang K, Fornek JL, Molteni A, Engman DM. Captopril prevents experimental autoimmune myocarditis. J. Immunol. 171, 346-352 (2003).
26. Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, Kishimoto C. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: Anti-inflammatory effects associated with antioxidant property. Am. J. Physiol. Heart Circ. Physiol. 286(1), H83-H90 (2004).
27. Saltzberg MI, Szmkiewiez S, Bianco NR. Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using wearable cardiac defibrillator. J. Card. Fail. 18, 21-27 (2012).
28. Fett JD. Some peripartum cardiomyopathy mothers are still at risk for sudden cardiac death. J. Card. Fail. 18, 262 (2012).
29. Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur. J. Heart Fail. 4, 305-309 (2002).
30. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin. Proc. 80, 1602-1606 (2005).
31. Fett JD, Carraway RD, Markham DW, Ernst S. Pentoxifylline treatment for peripartum cardiomyopathy J. Card. Fail. 19, 8S (2013).
32. Haghikia A, Podewski E, Libhaber E et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res. Cardiol. 108(4), 366 (2013).
33. Cooper LT, Mather PJ, Alexis JD, Pauly DF, Torre-Amione G, Wittstein IS et al. IMAC2 Investigators. Myocardial recovery in peripartum cardiomyopathy; prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J. Card. Fail. 18, 28-33 (2012).
34. McTiernan C, Hanley-Yanez K, Pisarcik JE et al.; for the IPAC investigators. Activation of cellular immunity in peripartum cardiomyopathy: Results of the multicenter IPAC Registry. Circulation 124, A14173 (2011).
35. Hilfiker-Kleiner D, Kaminski K, Podewski E et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128, 589-600 (2007).
36. Sliwa K, Blauwet L, Tibazarwa K et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy. A proof-of-concept pilot study. Circulation 121, 1465-1473 (2010).
37. Walenta K, Schwarz V, Schirmer SH et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur. Heart J. 33, 1469-1479 (2012).
38. Patten IS, Rana S, Shahul S et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485, 333-338 (2012).
39. Rana S, Powe CE, Salahuddin S et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125, 911-919 (2012).
40. Perni U, Sison C, Sharma V et al. Angiogenic factors in superimposed preeclampsia: A longitudinal study of women with chronic hypertension during pregnancy. Hypertension 59, 740-746 (2012).
41. Fett JD, Sundstrom JB, Ansari, AA. Evidence that plasma C-reactive protein may provide diagnostic help in peripartum cardiomyopathy. Circulation 116(Suppl. 2), Abstract 1959 (2007).
42. Huang GY, Zhang LY, Long-Le MA, Le-Xin Wang. Clinical characteristics and risk factors for peripartum cardiomyopathy. Afr. Health Sci. 12, 26-31 (2012).
43. Sliwa K, Förster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA. Peripartum cardiomyopathy: Inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur. Heart J. 27, 441-446 (2006).
44. Warraich RS, Fett JD, Damasceno A et al. Impact of pregnancy related heart failure on humoral immunity: Clinical relevance of G3-subclass immunoglobulinss in peripartum cardiomyopathy. Am. Heart J. 150, 263-269 (2005).
45. Muscaro-Blanco A, Alvarez K, Yu X et al. Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. Autoimmunity 41, 442-453 (2008).
46. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, Lohse MJ. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J. Clin. Invest. 113, 1419-1429 (2004).
47. Brar SS, Khan SS, Sandhu GK et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am. J. Cardiol. 100, 302-304 (2007).
48. Goland S, Modi K, Hatamizadeh P, Elkayam U. Differences in clinical profile of African-American women with peripartum cardiomyopathy in the United States. J. Card. Fail. 19(4), 214-218 (2013).
49. Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL. African-American women have a higher risk for developing peripartum cardiomyopathy. J. Am. Coll. Cardiol. 55, 654-659 (2010).
50. Bieteker M, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum cardiomyopathy: An indication for long-term follow-up and sustained therapy. Eur. J. Heart Fail. 14, 895-901 (2012).